OKYO Pharma Advances Urcosimod into Phase 3 Trial After Positive FDA Feedback — OKYO Pharma Limited

Event summary

OKYO Pharma received positive feedback from an FDA Type D meeting, validating its Phase 3 trial design for urcosimod.
The NEPTUNE global trial will enroll approximately 111 subjects in a 2:1 randomization of 0.05% urcosimod versus placebo.
OKYO plans to seek FDA Breakthrough Therapy Designation (BTD) to accelerate development and review.
Urcosimod is the first investigational therapy with an open IND specifically for neuropathic corneal pain (NCP).
The Phase 3 trial is expected to begin in the second half of 2026.

The big picture

OKYO Pharma's strategic shift into a global Phase 3 trial for urcosimod follows positive FDA feedback, reducing regulatory uncertainty and accelerating its clinical development pathway. The move underscores the company's commitment to addressing neuropathic corneal pain, a condition with no approved therapies, highlighting the potential for urcosimod to become a first-in-class treatment. The FDA's alignment on a single-dose study design and potential single-trial registration pathway further strengthens OKYO's position in the biopharmaceutical space.

What we're watching

Regulatory Pathway: Whether the FDA Breakthrough Therapy Designation will further accelerate urcosimod's development and review process.
Clinical Execution: The pace at which OKYO Pharma can enroll subjects in the NEPTUNE trial and generate meaningful data for regulators.
Market Opportunity: How successful Phase 3 results could position urcosimod as a first-in-class treatment for neuropathic corneal pain, addressing a significant unmet medical need.